Establishes under the direction of the state board of pharmacy a drug repository program to accept and dispense donated prescription drugs; authorizes such board and the commissioner of health to promulgate rules and regulations; makes definitions; exempts such persons or entities who dispense such donated drugs from criminal or tort liability or professional disciplinary action.
A03310 would create a statewide drug repository program under the State Board of Pharmacy to collect and redistribute donated prescription drugs to eligible New York residents. The bill allows donations from individuals, drug manufacturers, health care facilities, government entities, pharmacies, hospitals, and nonprofit clinics, but limits acceptance to prescription drugs that are in original sealed, tamper-evident packaging, are not expired within six months, and are not adulterated. The program would also allow unused Medicaid-dispensed prescription drugs to be accepted under certain conditions.
The bill directs the State Board of Pharmacy, in consultation with the Commissioner of Health, to adopt detailed rules governing eligibility, storage, inspection, dispensing, donor forms, recipient identification, handling fees, and lists of drugs that may or may not be accepted. Pharmacies, hospitals, and nonprofit clinics that choose to participate would dispense donated drugs only by prescription and could charge a handling fee to cover restocking and dispensing costs. The bill also authorizes the board to establish standards for economic eligibility and recipient verification, and it takes effect 180 days after becoming law, with immediate authorization for necessary regulatory preparation.
The bill would add a new section 6833 to the Education Law and expand the regulatory authority of the State Board of Pharmacy and the Commissioner of Health over donated prescription drug redistribution. It would create a new legal framework for accepting, storing, inspecting, and dispensing donated medications, while also setting conditions for participation by pharmacies, hospitals, and nonprofit clinics. The bill further provides broad immunity from criminal prosecution, civil liability, and professional discipline for covered participants acting reasonably and in good faith, and it bars resale of donated drugs.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears supportive and policy-oriented, with the measure framed as a public-benefit program to improve access to medications for low-income and uninsured residents. The bill’s structure suggests an effort to balance access with safety by imposing packaging, expiration, inspection, and regulatory requirements. No formal opposition or recorded vote history is provided in the materials, so there is no documented partisan or procedural sentiment to assess beyond the bill’s apparent charitable and access-to-care purpose.
The main points of potential contention are likely to be patient safety, liability, and administrative burden. The bill addresses safety concerns by limiting donations to sealed, tamper-evident drugs and excluding drugs that are expired, adulterated, or subject to manufacturer registration requirements, but some may still question whether donated medications can be reliably screened and stored. Another possible issue is the scope of immunity, which shields donors, participating facilities, regulators, and manufacturers from civil, criminal, and disciplinary liability when acting in good faith. Participation is voluntary, which may reduce opposition from providers, but the handling fee, eligibility rules, and implementation standards could still be debated by pharmacies, hospitals, nonprofit clinics, and regulators.